New Treatment Options for Patients With Bladder Cancer

Presenter: Thomas W. Flaig

Bladder cancer is not rare—in men, it is the fourth most common cancer and the eighth leading cause of cancer-related death. The emergence of new systemic therapies, approval of PD-1 and PD-L1 inhibitors, and progress in the development of biomarkers have revolutionized the treatment of this urologic malignancy. The current NCCN Guidelines, which reflect the most up-to-date, evidence-based data relating to the evaluation and management of bladder cancer, support the incorporation of some of these novel therapeutics into clinical practice.

Disclosures: Dr. Flaig has disclosed receiving grant/research support from Agensys, Inc., Astellas Pharma US, Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, Inc., Janssen Pharmaceutica Products, LP, Merck & Co., Inc., sanofi-aventis U.S., and Seattle Genetics, Inc; serving as a scientific advisor for Janssen Pharmaceutica Products, LP, and Seattle Genetics, Inc.; and receiving equity interest/stock options in and intellectual property rights for Aurora Oncology.

Correspondence: Thomas W. Flaig, MD, University of Colorado, Mail Stop F520, 13001 East 17th Place, Aurora, CO 80045. Email: thomas.flaig@cuanschutz.edu
  • 1.

    Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:733.

  • 2.

    Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214218.

  • 3.

    Flaig TW, Spiess PE, Abern M, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Bladder Cancer. Version 1.2022. Accessed March 31, 2022. Available at NCCN.org

    • Search Google Scholar
    • Export Citation
  • 4.

    Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021;22:919930.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Gill J, Prasad V. Pembrolizumab for non–muscle-invasive bladder cancer—a costly therapy in search of evidence. JAMA Oncol 2021;7:501502.

  • 6.

    Steinberg RL, Thomas LJ, Brooks N, et al. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol 2020;203:902909.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:10151026.

  • 8.

    Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 2021;384:21022114.

  • 9.

    Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383:12181230.

  • 10.

    Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384:11251135.

  • 11.

    Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 2021;39:24742485.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019;381:338348.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 711 711 711
PDF Downloads 416 416 416
EPUB Downloads 0 0 0